Germany is represented in JPIAMR by the Federal Ministry of Education and Research (BMBF).

Infectious diseases are the most common cause of death worldwide. In Germany, more than 40,000 people died of the consequences of an infection in 2006. Since the percentage of resistant pathogens has risen in recent years, and a further increase cannot be ruled out, a targeted approach is needed to reduce antimicrobial resistance and strengthen preventive measures at the local, regional and national level. The containment of antimicrobial resistance necessitates a comprehensive examination of the problem, since antimicrobial resistance occurs both in the field of human medicine and in veterinary medicine. Consequently, an Antimicrobial Resistance Strategy for Germany was developed in 2008.
Thus, besides the national engagement in research in this field and the implementation of a German Antibiotic Resistance Strategy, coordinating and strengthening the European research efforts is a particular concern.

Germany represented by the Federal Ministry of Education and Research (BMBF) is partner in the development and implementation of JPIAMR.

National AMR research program and activities

AMR Research program

  • With the “German One Health Initiative” (GOHI), the Federal Institute for Risk Assessment (BfR), the Friedrich Loeffler Institute (FLI), the Paul Ehrlich Institute (PEI) and the Robert Koch-Institute (RKI) founded a platform for networking of the four sectoral research institutions. In the first round, funding was provided for several PhD theses dealing with data on antimicrobial resistance in humans and animals and with the appearance of resistance in specific pathogens. (2017)
  • BMBF: “National research network on zoonotic infectious diseases”, 2017. The goal is to develop the One Health approach further and to build up a closer connection between research and the healthcare sector, so that the results can be used more quickly in the public health services in human and veterinary medicine.
  • National Drug Initiative: In April 2017, the German Bundestag adopted the National Drug Initiative to safeguard and strengthen R&D on anti-infectives. The aim of the initiative is to support drug development, especially in the field of antiinfectives and antibiotic resistance, and to strengthen cooperation between science and industry. Junior research groups in infection research: The aim of the initiative is to promote the career path of qualified young scientists in clinical and application-oriented infection research and to establish them in the scientific system.
  • National Research Platform for Zoonoses and Research Network: The platform was established to strengthen the coordination and networking of cooperation within research activities on zoonotic infectious diseases, i.e. diseases transmissible between humans and animals. The platform is supported by the BMBF, BMEL, BMG and BMVg and by the departmental research institutions of the BMG, BMEL and BMVg.

National AMR research calls

  • BMBF: “Sino-German Call for Projects on Antimicrobial Resistance”, 2020
  • BMBF: “French-German Call for Projects on Antimicrobial Resistance”, 2020
  • BMBF: “French-German Call for Projects on Antimicrobial Resistance”, 2019
  • BMBF: “Junior research groups in infection research”, 2019
  • BMBF: “Drug development based on natural substances for the control of infectious diseases”, 2018
  • The federal Ministry of Health (BMG): “Integrated genome-based surveillance of zoonotic pathogens and pathogens with special antimicrobial resistance”, 2018
  • BMBF: “Target validation for pharmaceutical drug development”, 2017
  • BMBF: “Diagnostics and new types of therapy to treat bacterial infections”, 2016

Activities on AMR actions at national level

  • Contribution to international AMR research programs and activities:
    • Since 2019 BMBF participates in the Combating Antibiotic Resistant Biopharmaceutical Accelerator (CARB-X) initiative. The BMBF supports this global partnership with around € 40 million.
    • Since 2018 BMBF invests € 50 million into all business activities of the Global Antibiotic Research and Development Partnership (GARDP).
    • Since 2018 BMBF supports the Global AMR R&D Hub (Global Antimicrobial Resistance Research and Development Hub) by financing its secretariat for three years with € 1.8 million. Germany plays an active Role in the Board of Members with its representative holding the position as chair. In addition, the German Ministry of Health (BMG) is supporting the Hub financially for some of its endeavours regarding the Dynamic Dashboard.
    • Since 2017 BMZ and BMBF supports the ESTHER Clinic Partnerships where Research projects on AMR, tuberculosis and HIV in African hospitals is funded with € 900 thousand.
  • In implementation of the G20 declarations, the first meeting of representatives of Public Health and Veterinary Public Health Institutes of the G20 took place 2017 in Berlin with the aim of strengthening the One Health approach. Representatives of international organisations such as the World Health Organization (WHO) and the World Organisation for Animal Health (OIE) also participated.
  • BMBF was co-organiser of the Grand Challenges Meeting of the Bill and Melinda Gates Foundation in October 2018 in Berlin. Together with the Wellcome Trust and other German ministries, the BMBF organised the part of the event dealing with antimicrobial resistance.
  • World Health Summit October 2018 in Berlin.
  • Since 2021 “Academia and industry united innovation and treatment for tuberculosis (UNITE4TB)“ of the Innovative Medicines Initiative (IMI). The aim of UNITE4TB is to accelerate the clinical evaluation of existing and novel drug combinations and to built a global clinical trials network equipped to implement phase 2 trials that conform to the highest regulatory standards. The BMBF supports UNITE4TB with around € 25 million €.

National action plans

Management Board representatives

  • Barbara Junker, Deutsches Zentrum für Luft- und Raumfahrt (DLR)
  • Joachim Klein, Federal Ministry of Education and Research